Drug intelligence / Profile preview

MR-MC-01

Development stage: Phase 1
Lead developer: Mirae Cell Bio
Modality: Stem Cell Therapies → Cell Therapies
Administration: Submucosal Injection, Intravesical

Overview

MR-MC-01 is a cell therapy consisting of human embryonic stem cell (hESC)-derived mesenchymal stem cells (MSCs). It is being developed by Medytox for the treatment of interstitial cystitis (IC), also known as bladder pain syndrome. Unlike adult tissue-derived MSCs, hESC-derived MSCs offer a more consistent and scalable source of cells with high proliferative capacity. The therapy aims to alleviate the chronic inflammation and tissue damage associated with IC by leveraging the immunomodulatory and regenerative properties of MSCs, potentially repairing the bladder lining and reducing pain symptoms.

Other names: hESC-derived mesenchymal stem cellshuman embryonic stem cell-derived mesenchymal stem cells

Beyond the preview

Go deeper on MR-MC-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MR-MC-01.

Explore the full profile